Skip to NavigationSkip to content

Radius bolsters leadership with appointment of Novo Vet

Published on: 18/07/17

Jesper Høiland has been revealed as the new President and Chief Executive Officer of Radius. The news comes shortly after it was revealed that Amgen’s rival osteoporosis drug had been rejected by the FDA.

The move to replace long-standing CEO, Bob Ward, was explained as a decision to bolster the company’s experience of successfully launching products into the market. Høiland has experience launching across the US, where he was responsible for the launch of four products in the preceding four years at Novo Nordisk.

Upon leaving Novo, Høiland had worked for the company close to 30 years – ending his time with the company as President and Executive Vice President of operations in the US. This experience will be called on for the launch of Radius’ drug Tymlos, a part of his role that he specifically referenced upon accepting the position.

"I am delighted to be joining Radius in the exciting, early stages of the commercialization of Tymlos," said Jesper Høiland, "and I look forward to guiding the continued development of its strong pipeline. I am eager to work with our board, senior management and the entire organization to execute on our promising future and deliver on the Company's long-standing goal of positively impacting the lives of patients and delivering significant value for all our stakeholders."

Kurt Graves, Chairman of the Board, explained the decision to replace previous CEO, Ward, with Høiland: "We are pleased to welcome Jesper to Radius Health at this important time, and believe that he is uniquely qualified to lead Radius through the successful launch of Tymlos, and the advancement of our exciting clinical stage assets including elacestrant.  Throughout his US and Global leadership roles at Novo Nordisk, he has demonstrated success in launching major brands, executing on business development and driving sustainable growth.  His leadership and experience will be invaluable in guiding Radius through our next dynamic period of growth."

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches